Alto Neuroscience (NYSE:ANRO) Given New $55.00 Price Target at HC Wainwright

Alto Neuroscience (NYSE:ANRO) had its target price hoisted by HC Wainwright from $50.00 to $55.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 63.54% from the company’s current price.

ANRO has been the topic of several other research reports. Bank of America started coverage on Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Wolfe Research initiated coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Finally, BTIG Research upped their price target on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.25.

Alto Neuroscience Stock Performance

Alto Neuroscience stock traded up $1.49 during midday trading on Monday, hitting $33.63. 250,108 shares of the company’s stock were exchanged, compared to its average volume of 371,723. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -13.87 and a beta of 1.06. Alto Neuroscience has a 12-month low of $3.05 and a 12-month high of $33.99. The firm’s 50 day simple moving average is $25.97 and its 200 day simple moving average is $22.79.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. Equities research analysts predict that Alto Neuroscience will post -3 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in Alto Neuroscience in the fourth quarter valued at $62,000. GK Wealth Management LLC purchased a new position in shares of Alto Neuroscience in the 2nd quarter valued at about $226,000. Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $198,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $221,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Alto Neuroscience during the fourth quarter worth about $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.